Menu Investors Company Information Overview Press Releases Events + Presentations Company Information Stock Information Analyst Coverage SEC Filings Corporate Governance News Alerts Company Profile Vallon Pharmaceuticals (NASDAQ: VLON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. Leveraging the clinical success of dextroamphetamine, we are developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is expected to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine. Leadership David Baker, President & CEO Tim Whitaker, M.D., Chief Medical Officer Penny Toren, Senior VP, Regulatory Affairs & Project Management Leanne Kelly, Chief Financial Officer IR Contacts Investor & Media Relations Jenene Thomas JTC IR vallon@jtcir.com (833) 475-8247 Transfer Agent VStock Transfer LLC l-z@vstocktransfer.com (212) 828-8436 U.S. Legal Council Thompson Hine LLP 335 Madison Ave, 12th Floor New York, NY 10017 (212) 908-3905 Auditor EisnerAmper 111 Wood Ave S. Iselin, NJ 08830 (732) 243-7000 Frequently Asked Questions How is Vallon stock traded? Can I buy stock directly from Vallon? How do I get my purchased shares? What is Vallon’s CUSIP number? What is Vallon’s industry classification? Who can I contact for general information about Vallon? Where is Vallon’s corporate headquarters? When was Vallon incorporated? When is Vallon’s fiscal year end? Who are Vallon’s independent auditors? Who is Vallon’s outside legal counsel? Sign Up for Updates © 2021 Vallon Pharmaceuticals | Terms of Use | Privacy Policy ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.